TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02824601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: 1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: 1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Description: 2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
Study: NCT01878084

Intervention type: OTHER
Group type: OTHER
Intervention: bioactive glass (sol-gel)
Description: Extraction sockets will be augmented using bioactive glass (sol-gel)

Intervention type: OTHER
Group type: OTHER
Intervention: empty extraction socket
Description: Extraction socket will be left empty
Study: NCT02232828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective removal
Description: Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise removal
Description: Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described.
Study: NCT02877095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: subcutaneous furosemide delivered via subcutaneous pump
Study: NCT00003779

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Connaught
Description: Compare two strains of BCG

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tice
Description: Compare two strains of BCG
Study: NCT04282317

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan
Description: MRI scan

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan
Description: MRI scan
Study: NCT01293019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Real treatment of osteopathy
Study: NCT00831545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
Study: NCT01293019

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Placebo
Description: Sham treatment of osteopathy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Classical treatment of pain in cystic fibrosis patients
Study: NCT01556815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorafenib in combination with TACE
Description: Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
Study: NCT04561882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter exclusion of atrial septal aneurysm
Description: Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)
Study: NCT02960763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Augmentation
Description: Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Augmentation
Description: Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to bupropion
Description: Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Augmentation
Description: Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to nortriptyline
Description: Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
Study: NCT02085538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: palbociclib 125 mg oral capsule with food once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: palbociclib 125 mg oral capsule with food once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: palbociclib 125 mg oral capsule with food once
Study: NCT00831545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
Study: NCT02538289

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teaching talks
Description: Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teaching talks
Description: Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
Study: NCT03683693

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin group
Description: The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT \< 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT \< 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion.
Study: NCT03397329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-348 Sequence A
Description: 1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-348 Sequence B
Description: 1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)
Study: NCT01820572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Study: NCT04423770

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; this is a purely observational study
Study: NCT02002312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTA-girentuximab
Description: Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments.
Study: NCT04324346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC75 (or EC90) x 6
Description: Type of Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC75 (or EC90) x 6
Description: Type of Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC100 + Taxotere (EC90 + Taxotere) 3+3
Description: Type of Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC100 + Taxotere (EC90 + Taxotere) 3+3
Description: Type of Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Type of Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Type of Chemotherapy
Study: NCT01144676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: 25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: 25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
Study: NCT01098656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)
Study: NCT01450826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
Study: NCT01354665

Intervention type: BIOLOGICAL
Intervention: Interferon beta-1b (Betaferon, BAY86-5046)
Description: Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
Study: NCT04634240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: PCI of all qualifying lesions.
Study: NCT03992170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
Study: NCT02630329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vNOTES adnexectomy
Description: Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adnexectomy
Description: Surgical removal of one or both adnexa by transabdominal laparoscopy
Study: NCT01620775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRIs
Description: Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs
Description: Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs
Description: Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs
Description: Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain testing
Description: There will be a 1-1.5 hour session including pain tolerance testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain testing
Description: There will be a 1-1.5 hour session including pain tolerance testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain testing
Description: There will be a 1-1.5 hour session including pain tolerance testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain testing
Description: There will be a 1-1.5 hour session including pain tolerance testing.
Study: NCT01740076

Intervention type: OTHER
Group type: OTHER
Intervention: soy nuts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soy nuts
Study: NCT00852215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus stent
Description: Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vision stent
Description: Stenting with VISION coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study
Study: NCT04058535

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: Aflibercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-L9
Description: Aflibercept biosimilar
Study: NCT02680834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Action Pneumatic Compression Device
Description: Dual action pneumatic compression device used to treat chronic VLUs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Layer Bandaging
Description: Multi-layer bandaging used to treated chronic VLUs
Study: NCT04033341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3214996
Description: Administered orally
Study: NCT03228524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Aspartate
Description: Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
Study: NCT02085538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib
Description: palbociclib 125 mg oral capsule with food once
Study: NCT03813550

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal and blood samples
Description: Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
Study: NCT03418870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
Study: NCT01828190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
Study: NCT01868035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tositumomab and iodine I-131 tositumomab
Description: Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass.
Study: NCT02318719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Study: NCT03228524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Standard physiotherapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic exercise
Description: Standard physiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT04973371

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test
Description: Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® \[Cepheid, Sunnyvale, CA\] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
Study: NCT01570270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CLA enriched cheese
Description: This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.